GRAIL, Inc.(GRAL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GRAL GRAIL, Inc.

盘前交易 10-22 07:05:10 EDT

132.60

+7.93

+6.36%

盘前130.10

-2.50-1.89%

05:05 EDT

最高134.91	最低123.20	成交量59.95万
今开123.88	昨收124.67	日振幅9.39%
总市值59.23亿	流通市值54.01亿	总股本4,467万
成交额7,911万	换手率1.47%	流通股本4,073万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":132.6,"timestamp":1792612800000,"preClose":124.67,"halted":0,"volume":599536,"hourTrading":{"tag":"盘前","latestPrice":130.0988,"preClose":132.6,"latestTime":"05:05 EDT","volume":17,"amount":2193.49419,"timestamp":1792659908250,"change":-2.5012,"changeRate":-0.018863,"amplitude":0.014697},"delay":0,"changeRate":0.06360792492179347,"floatShares":40727891,"shares":44666200,"eps":-9.748709,"marketStatus":"盘前交易","change":7.93,"latestTime":"10-22 07:05:10 EDT","open":123.875,"high":134.91,"low":123.2,"amount":79114506.76416,"amplitude":0.093928,"askPrice":141.22,"askSize":100,"bidPrice":128.01,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-9.748709,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792675800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":132.6,"preHourTrading":{"tag":"盘前","latestPrice":130.0988,"preClose":132.6,"latestTime":"05:05 EDT","volume":17,"amount":2193.49419,"timestamp":1792659908250,"change":-2.5012,"changeRate":-0.018863,"amplitude":0.014697},"postHourTrading":{"tag":"盘后","latestPrice":131.5,"preClose":132.6,"latestTime":"19:56 EDT","volume":10846,"amount":1437964.55,"timestamp":1792627017233,"change":-1.1,"changeRate":-0.008296,"amplitude":0.008296},"volumeRatio":0.7221911636031405,"impliedVol":0.9667,"impliedVolPercentile":0.64},"requestUrl":"/m/hq/s/GRAL/wiki","defaultTab":"wiki","newsList":[{"id":"1112451021","title":"异动解读｜GRAIL盘中上涨5.35%，FDA审评利好后获投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1112451021","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112451021?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:30","pubTimestamp":1792593040,"startTime":"0","endTime":"0","summary":"10月21日，GRAIL盘中上涨5.35%，报131.34美元／股，成交额1421.59万美元。消息面上，公司Galleri多癌早检产品此前获美国FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级，继续强化市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比；市场关注点已更多转向产品定位与标签，而非核心安全问题，成为股价近期活跃的重要催化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL股价上涨，FDA利好催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180942414","title":"异动解读｜GRAIL盘前上涨7.82%，FDA审评利好后获投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180942414","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180942414?lang=zh_cn&edition=full","pubTime":"2026-10-20 19:14","pubTimestamp":1792494877,"startTime":"0","endTime":"0","summary":"10月20日，GRAIL盘前上涨7.82%，报131.99美元／股，成交额2.35万美元。消息面上，公司Galleri多癌早检产品此前获美国FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级，强化了市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比。此前机构还指出，FDA讨论焦点已收窄至产品定位与标签，而非核心安全问题，成为股价近期活跃的重要催化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FDA审评利好，GRAIL获投行大幅上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130423029","title":"异动解读｜GRAIL盘中上涨5.05%，FDA审评利好后获投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1130423029","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130423029?lang=zh_cn&edition=full","pubTime":"2026-10-20 03:17","pubTimestamp":1792437421,"startTime":"0","endTime":"0","summary":"10月20日，GRAIL盘中上涨5.05%，报123.76美元／股，成交额4606.8万美元。消息面上，此前公司Galleri多癌早检产品先获美国FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级，继续强化市场对其监管落地与商业化前景的预期。从审评进展看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比；更早前UBS指出，FDA讨论焦点已收窄至产品定位与标签，而非核心安全问题。这成为近期股价反复活跃的关键催化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FDA审评利好，GRAIL获投行大幅上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193082740","title":"异动解读｜GRAIL, Inc.盘中下跌6.16%，报127.1168美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193082740","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193082740?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:57","pubTimestamp":1792159022,"startTime":"0","endTime":"0","summary":"10月16日，GRAIL, Inc.盘中下跌6.16%，报127.1168美元/股，成交额1146.87万美元。GRAIL, Inc.所在的生物科技行业中，Moderna, Inc.下跌8.57%，艾伯维公司上涨0.2%，安进上涨0.44%，吉利德科学下跌0.66%，福泰制药下跌0.06%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169929282","title":"异动解读｜GRAIL盘中上涨5.56%，FDA顾问委员会积极评估催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1169929282","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169929282?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:39","pubTimestamp":1791553182,"startTime":"0","endTime":"0","summary":"10月9日，GRAIL盘中上涨5.56%，报138.66美元/股，成交额667.56万美元。消息面上，FDA分子与临床遗传学器械顾问委员会对Galleri多癌种早检产品的积极投票结果持续发酵，资本市场连续多日反映该催化效应。PATHFINDER 2研究亦显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。尽管顾问委员会意见对FDA不具约束力，最终审批结果仍待公布，但市场情绪已明显偏向乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"癌症早检获FDA积极评估，GRAIL盘中上扬","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197444992","title":"异动解读｜GRAIL盘中上涨5.14%，FDA顾问委员会积极评估催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1197444992","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197444992?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:34","pubTimestamp":1791293671,"startTime":"0","endTime":"0","summary":"10月6日，GRAIL盘中上涨5.14%，报166.0美元/股，成交额1666.97万美元。消息面上，FDA分子与临床遗传学器械顾问委员会对Galleri多癌种早检产品的积极投票结果持续发酵，资本市场连续多日反映该催化效应。此前公布的结果显示，Galleri安全性以10:0全票通过，有效性6:4通过，获益风险7:2通过。尽管顾问委员会意见对FDA不具约束力，最终审批结果仍待公布，但市场情绪已明显偏向乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GRAIL盘中大涨，FDA积极评估持续催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178518451","title":"异动解读｜GRAIL盘前上涨6.76%，FDA顾问委员会利好催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1178518451","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178518451?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:18","pubTimestamp":1791278329,"startTime":"0","endTime":"0","summary":"10月6日，GRAIL盘前上涨6.76%，报156.93美元/股，成交额16.27万美元。此前FDA分子与临床遗传学器械顾问委员会对Galleri投票结果积极：安全性10:0全票通过，有效性6:4通过，获益风险7:2通过。PATHFINDER 2研究亦显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。尽管顾问委员会意见对FDA不具约束力，最终审批结果仍待公布，但资本市场已连续多日反映该催化效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA利好持续发酵，GRAIL盘前冲高","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116494514","title":"异动解读｜GRAIL盘中上涨5.13%，UBS大幅上调目标价至175美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116494514","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116494514?lang=zh_cn&edition=full","pubTime":"2026-10-05 23:53","pubTimestamp":1791215598,"startTime":"0","endTime":"0","summary":"10月5日，GRAIL盘中上涨5.13%，报150.61美元/股，成交额5011.85万美元。消息面上，瑞银最新将GRAIL目标价从105美元大幅上调至175美元，维持买入评级。此次异动延续了9月下旬以来FDA顾问委员会对Galleri多癌种早检产品的积极评估催化效应——此前委员会投票中安全性10:0全票通过，获益风险7:2通过。需注意FDA最终审批仍需等待正式结果公布。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153892212","title":"异动解读｜GRAIL盘中上涨6%，FDA顾问委员会利好催化延续推动股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1153892212","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153892212?lang=zh_cn&edition=full","pubTime":"2026-10-02 21:47","pubTimestamp":1790948837,"startTime":"0","endTime":"0","summary":"10月2日，GRAIL盘中上涨6%，报140.38美元/股，成交额941.74万美元。此前盘中曾因短期获利回吐一度走低，随后快速反弹。消息面上，FDA分子与临床遗传学器械顾问委员会此前对GRAIL旗下Galleri多癌种早检产品投票结果积极——安全性10:0全票通过、有效性6:4通过、获益风险7:2通过。PATHFINDER 2研究显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。需注意，顾问委员会意见对FDA不具约束力，最终正式审批结果仍待公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA利好催化延续，GRAIL盘中上涨6%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158000170","title":"异动解读｜GRAIL盘中下跌5.07%，FDA顾问委员会利好消化后股价回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1158000170","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158000170?lang=zh_cn&edition=full","pubTime":"2026-10-02 03:55","pubTimestamp":1790884530,"startTime":"0","endTime":"0","summary":"10月2日，GRAIL盘中下跌5.07%，报133.01美元/股，成交额1.17亿美元。消息面上，此前FDA分子与临床遗传学器械顾问委员会对旗下Galleri多癌种早检产品投票结果积极——安全性10:0全票通过、有效性6:4通过、获益风险7:2通过，推动股价自9月下旬以来大幅走高。随着顾问委员会催化逐步被市场消化，短期获利回吐压力显现。顾问委员会意见对FDA不具约束力，最终正式审批结果仍待公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"GRAIL股价回落，FDA利好消化后承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100526236","title":"异动解读｜GRAIL盘中上涨5.27%，FDA顾问委员会全票通过Galleri安全性并支持获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1100526236","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100526236?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:07","pubTimestamp":1790777220,"startTime":"0","endTime":"0","summary":"消息面上，FDA分子与临床遗传学器械顾问委员会此前就GRAIL旗下Galleri多癌种早期检测产品的上市前批准申请进行投票，10名委员以10:0全票通过安全性，6:4通过有效性，7:2认定该产品对50岁及以上成人的临床获益大于风险。此前PATHFINDER 2研究显示，Galleri联合常规筛查可将癌症检出率提升6.5倍，71%的新发现癌症处于I至III期。瑞银维持买入评级，认为顾问委员会的积极投票几乎\"消除了风险\"，市场对Galleri正式获批的预期持续升温，推动股价自9月下旬以来大幅走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA顾问委员会全票通过，GRAIL上涨","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194948486","title":"异动解读｜GRAIL盘中上涨5.69%，FDA顾问委员会投票支持Galleri癌症检测获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1194948486","media":"行情直击","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194948486?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:45","pubTimestamp":1790603132,"startTime":"0","endTime":"0","summary":"9月28日，GRAIL盘中上涨5.69%，报130.765美元/股，成交额1775.57万美元。消息面上，FDA分子与临床遗传学器械顾问委员会近日对GRAIL旗下Galleri多癌种早期检测产品的上市前批准申请进行投票，10名投票成员全票通过安全性，以6比4通过有效性，以7比2通过针对50岁及以上成人的获益-风险评估。顾问委员会的积极投票进一步推动市场对Galleri正式获批的乐观预期，股价延续近期上行趋势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA顾问委员会支持，GRAIL盘中上涨","news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199948635","title":"异动解读｜GRAIL盘中上涨5.97%，FDA顾问委员会投票支持Galleri癌症检测产品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1199948635","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199948635?lang=zh_cn&edition=full","pubTime":"2026-09-24 21:58","pubTimestamp":1790258310,"startTime":"0","endTime":"0","summary":"消息面上，FDA医疗器械咨询委员会分子与临床遗传学设备小组对Galleri多癌种早期检测产品的上市前批准申请进行了投票，10名投票成员全票通过其安全性，以6比4支持其有效性，以7比2认可其在50岁及以上成人中检测多种癌症的获益-风险比。此前FDA简报文件显示，该机构对Galleri的分析性能、桥接分析及主要安全性数据无重大疑问，讨论焦点集中在产品标签定位上。顾问委员会的积极投票为后续FDA正式批准奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA顾问委员会力挺，GRAIL盘中上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134221217","title":"暗流涌动：GRAIL股价因FDA会议文件公布而飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1134221217","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134221217?lang=zh_cn&edition=full","pubTime":"2026-09-22 06:58","pubTimestamp":1790031507,"startTime":"0","endTime":"0","summary":"周一，GRAIL公司股价大幅攀升34%，此轮涨势源于美国食品药品监督管理局在周四顾问委员会会议前夕发布了一系列文件。这些文件将对FDA是否批准该公司研发的多癌种血液检测产品起到决定性作用。自2021年起，GRAIL便以处方形式销售此产品，但FDA至今尚未批准任何一款用于筛查多种癌症的检测手段。然而，该检测对多数癌症病例未能及时发现。无论是上述美国研究，还是在涉及约14.2万人的英国试验中，Galleri仅能捕捉到约三分之一在一年内确诊的癌症病例。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","LABU","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180134132","title":"GRAIL宣布FDA咨询委员会会议将审议Galleri®多癌早检上市前申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1180134132","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180134132?lang=zh_cn&edition=full","pubTime":"2026-08-07 23:06","pubTimestamp":1786115182,"startTime":"0","endTime":"0","summary":"GRAIL（股票代码：GRAL）正式对外披露，美国食品药品监督管理局（FDA）已计划召开一场咨询委员会会议，专门针对其旗下面向多癌种早期检测的Galleri®检测产品，所提交的上市前批准申请（PMA）进行深入审议。这一里程碑式的进展，标志着该潜在颠覆性癌症筛查技术，在通往监管绿灯的道路上，迈出了至关重要的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191676874","title":"Priority Health携手GRAIL，成为密歇根州首个为雇主计划提供Galleri®多癌种早期检测血液测试的医疗计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1191676874","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191676874?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206891,"startTime":"0","endTime":"0","summary":"Priority Health与GRAIL, Inc.达成合作，开创密歇根州先河，成为该州首个将Galleri®多癌种早期检测血液测试纳入雇主医疗计划的健康保险机构。此项合作旨在通过前沿的液体活检技术，为参保员工提供更早发现多种癌症的机会，从而可能改善治疗结果并降低医疗成本。Galleri®测试能够通过单次抽血，筛查出50多种癌症的信号，其中包括许多缺乏常规筛查指南的癌症类型。这一举措标志着精准医疗和预防性健康管理在雇主福利领域的重要拓展，有望提升整体人群的健康水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104190016","title":"GRAIL在2026年ASCO年会上公布NHS-Galleri试验完整结果，显示晚期癌症诊断数量显著减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1104190016","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104190016?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:01","pubTimestamp":1780142464,"startTime":"0","endTime":"0","summary":"GRAIL公司在2026年美国临床肿瘤学会（ASCO）年会上，正式公布了其NHS-Galleri试验的完整数据。该试验结果明确显示，通过其多癌种早期检测血液检测技术Galleri，能够显著降低第四期（晚期）癌症的诊断数量。这一关键数据进一步验证了该检测方法在癌症早期发现与干预方面的潜在价值，为改善癌症患者预后提供了新的有力证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142483101","title":"财报前瞻｜GRAIL, Inc.本季度营收预计小幅增长，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1142483101","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142483101?lang=zh_cn&edition=full","pubTime":"2026-04-29 00:55","pubTimestamp":1777395357,"startTime":"0","endTime":"0","summary":"GRAIL, Inc.将于2026年05月05日美股盘后发布最新季度财报，市场关注收入增速能否延续、费用投放节奏与利润率改善。市场目前一致预期本季度GRAIL, Inc.营收为3,888.14万美元，同比增长10.46%；息税前亏损为1.26亿美元，同比增长11.44%；调整后每股收益为-2.76美元，同比增长32.45%。从近期针对GRAIL, Inc.的研究报道中，机构观点偏谨慎，关注点集中在收入增速放缓与费用投入的回报周期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜GRAIL, Inc.本季度营收预计小幅增长，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518022743","title":"Grail, Inc.盘中异动 急速跳水5.38%报31.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518022743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518022743?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613489,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Grail, Inc.股票出现异动，股价快速下跌5.38%。截至发稿，该股报31.11美元/股，成交量2.6055万股，换手率0.08%，振幅0.94%。Grail, Inc.股票所在的生命科学行业中，整体跌幅为0.54%。Grail, Inc.公司简介：GRAIL Inc是一家医疗保健公司，致力于开发用于早期癌症检测的技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213129a26a246b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213129a26a246b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517613371","title":"Grail, Inc.盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517613371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517613371?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:38","pubTimestamp":1741271897,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时38分，Grail, Inc.股票出现异动，股价快速下挫5.08%。Grail, Inc.股票所在的生命科学行业中，整体涨幅为0.78%。其相关个股中，Fulgent Genetics, Inc.、安奈特保险、Bioaffinity Technologies, Inc.涨幅较大，Mainz Biomed N.V.、Endra Life Sciences Inc.、Ispecimen Inc.较为活跃，换手率分别为0.60%、0.47%、0.42%，振幅较大的相关个股有Bioaffinity Technologies, Inc.、Biodesix, Inc.、Check-Cap Ltd.，振幅分别为15.27%、10.31%、8.96%。Grail, Inc.公司简介：GRAIL Inc是一家医疗保健公司，致力于开发用于早期癌症检测的技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223818963c4e79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223818963c4e79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GRAL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://grail.com;investors.grail.com","stockEarnings":[{"period":"1week","weight":-0.0508},{"period":"1month","weight":0.2281},{"period":"3month","weight":0.8846},{"period":"6month","weight":1.4366},{"period":"1year","weight":0.584},{"period":"ytd","weight":0.5492}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Grail, Inc.于2015年9月11日在特拉华州注册成立。该公司是一家医疗保健公司，致力于通过开创癌症早期检测的新技术来拯救生命和改善健康。该公司建立了一个由科学家、工程师和医生组成的多学科组织，它正利用下一代测序（NGS）、人群规模临床研究以及最先进的计算机科学和数据科学的力量来克服医学的最大挑战之一。该公司利用该公司的平台技术，开发了一种多癌症早期检测血液检测方法，在临床研究中证明了从一次抽血中就可以检测出50多种癌症类型，并能高度准确地定位癌症信号。","exchange":"NASDAQ","name":"GRAIL, Inc.","nameEN":"GRAIL, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRAIL, Inc.(GRAL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供GRAIL, Inc.(GRAL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"GRAIL, Inc.,GRAL,GRAIL, Inc.股票,GRAIL, Inc.股票老虎,GRAIL, Inc.股票老虎国际,GRAIL, Inc.行情,GRAIL, Inc.股票行情,GRAIL, Inc.股价,GRAIL, Inc.股市,GRAIL, Inc.股票价格,GRAIL, Inc.股票交易,GRAIL, Inc.股票购买,GRAIL, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRAIL, Inc.(GRAL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供GRAIL, Inc.(GRAL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}